Clinical Trial ProgressNo objective responses have been seen to date in patients treated at the 900mg dose level.
Market CompetitionThe rapid development of next-gen drugs in the treatment of HR+/HER2- breast cancer may pose challenges for OnKure's existing drug combinations, as newer drugs are seen as more advanced.
Regulatory And Safety ConcernsOncologists express concerns about balancing cancer treatment with managing side effects like hyperglycemia, highlighting a need for more selective drugs, which could impact OnKure's approach.